Plucinsky M C, Prorok J J, Alhadeff J A
Cancer. 1986 Oct 1;58(7):1484-7. doi: 10.1002/1097-0142(19861001)58:7<1484::aid-cncr2820580718>3.0.co;2-r.
Previous studies have demonstrated a variant form of beta-hexosaminidase in metastatic tumor tissue of human liver and in sera from cancer patients with liver metastases. The current investigation examined sera for the presence of the variant form of beta-hexosaminidase from a large and heterogeneous group of cancer patients (with different primary sites and differing degrees of metastatic involvement), from normal controls and pathological controls with nonmalignant diseases. Comparison of the total serum beta-hexosaminidase activity levels and the percentage of the total activity comprised of beta-hexosaminidase B (Hex B) revealed no significant differences (P greater than 0.01) between the three groups. Analytical isoelectric focusing indicated that the variant beta-hexosaminidase was present in 80% of 108 cancer patients, 37% of 27 pathological controls and 11% of 18 normal controls. Examination of subgroups of the cancer patients based on the extent of metastasis revealed that there was a significant increase in total serum beta-hexosaminidase activity and the presence of variant beta-hexosaminidase in the sera as the disease progressed. These results suggest that serum beta-hexosaminidase may be a useful marker for monitoring the progression of malignant disease.
先前的研究已证实在人类肝脏转移性肿瘤组织以及患有肝转移的癌症患者血清中存在一种变异形式的β-己糖胺酶。本研究检测了大量不同类型癌症患者（原发部位不同、转移程度各异）、正常对照以及患有非恶性疾病的病理对照血清中变异形式β-己糖胺酶的存在情况。对三组人群的血清总β-己糖胺酶活性水平以及由β-己糖胺酶B（Hex B）构成的总活性百分比进行比较，结果显示三组之间无显著差异（P大于0.01）。分析性等电聚焦表明，在108例癌症患者中有80%、27例病理对照中有37%以及18例正常对照中有11%存在变异型β-己糖胺酶。根据转移程度对癌症患者亚组进行检测发现，随着疾病进展，血清总β-己糖胺酶活性显著增加，且血清中存在变异型β-己糖胺酶。这些结果表明，血清β-己糖胺酶可能是监测恶性疾病进展的有用标志物。
